Literature DB >> 34202167

Konjac Glucomannan Attenuated Triglyceride Metabolism during Rice Gruel Tolerance Test.

Takumi Nagasawa1,2, Takao Kimura1,2,3, Akihiro Yoshida1,2,3, Katsuhiko Tsunekawa1,2,3, Osamu Araki1, Kazumi Ushiki1,2, Hirotaka Ishigaki1, Yoshifumi Shoho1, Itsumi Suda1,2, Suguru Hiramoto1,2, Masami Murakami1,2,3.   

Abstract

In a recent study, we showed that konjac glucomannan (KGM) inhibits rice gruel-induced postprandial increases in plasma glucose and insulin levels. To extend this research, we investigated the effects of KGM addition to rice gruel on pre- and postprandial concentrations of circulating lipoprotein lipase (LPL), glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1), hepatic triglyceride lipase (HTGL), free fatty acids (FFA), and triglycerides (TG). A total of 13 Japanese men, without diabetes, dyslipidemia, or gastrointestinal diseases, interchangeably ingested rice gruel containing no KGM (0%G), rice gruel supplemented with 0.4% KGM (0.4%G), and rice gruel supplemented with 0.8% KGM (0.8%G), every Sunday for 3 weeks. Blood samples were obtained at baseline and at 30, 60, and 120 min after ingestion to measure the abovementioned lipid parameters. Lipid parameters showed small, but significant, changes. Significant reductions were found in circulating FFA levels among all participants. Circulating TG levels significantly declined at 30 min and then remained nearly constant in the 0.8%G group but exhibited no significant difference in the 0%G and 0.4%G groups. Although circulating levels of LPL and GPIHBP1 significantly decreased in the 0%G and 0.4%G groups, they increased at 120 min in the 0.8%G group. Participants in the 0%G and 0.4%G groups showed significant decreases in circulating HTGL levels, which was not observed in the 0.8%G group. Our results demonstrate the novel pleiotropic effects of KGM. Supplementation of rice gruel with KGM powder led to TG reduction accompanied by LPL and GPIHBP1 elevation and HTGL stabilization, thereby attenuating TG metabolism.

Entities:  

Keywords:  dietary supplements; glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1); hepatic triglyceride lipase (HTGL); konjac glucomannan; lipoprotein lipase (LPL); rice gruel; triglyceride

Year:  2021        PMID: 34202167     DOI: 10.3390/nu13072191

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  30 in total

1.  Interaction of bile acids, phospholipids, cholesterol and triglyceride with dietary fibers in the small intestine of rats.

Authors:  K Ebihara; B O Schneeman
Journal:  J Nutr       Date:  1989-08       Impact factor: 4.798

2.  An automated method for measuring lipoprotein lipase and hepatic triglyceride lipase activities in post-heparin plasma.

Authors:  Kiyomi Nakajima; Tetsuo Machida; Shigeyuki Imamura; Daisuke Kawase; Kazuya Miyashita; Isamu Fukamachi; Masahiro Maeda; Yuji Muraba; Takafumi Koga; Junji Kobayashi; Takao Kimura; Katsuyuki Nakajima; Masami Murakami
Journal:  Clin Chim Acta       Date:  2018-09-12       Impact factor: 3.786

3.  Triglyceride-rich lipoproteins and plasma lipid transport.

Authors:  Richard J Havel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01       Impact factor: 8.311

Review 4.  Konjac glucomannan, a promising polysaccharide of Amorphophallus konjac K. Koch in health care.

Authors:  Sudhanshu S Behera; Ramesh C Ray
Journal:  Int J Biol Macromol       Date:  2016-07-30       Impact factor: 6.953

5.  The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome.

Authors:  Takashi Shirakawa; Katsuyuki Nakajima; Shin-ichi Yatsuzuka; Younosuke Shimomura; Junji Kobayashi; Tetsuo Machida; Hiroyuki Sumino; Masami Murakami
Journal:  Clin Chim Acta       Date:  2014-10-27       Impact factor: 3.786

Review 6.  Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus.

Authors:  V Vuksan; J L Sievenpiper; Z Xu; E Y Wong; A L Jenkins; U Beljan-Zdravkovic; L A Leiter; R G Josse; M P Stavro
Journal:  J Am Coll Nutr       Date:  2001-10       Impact factor: 3.169

Review 7.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

8.  Globin digest, acidic protease hydrolysate, inhibits dietary hypertriglyceridemia and Val-Val-Tyr-Pro, one of its constituents, possesses most superior effect.

Authors:  K Kagawa; H Matsutaka; C Fukuhama; Y Watanabe; H Fujino
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

9.  Glucomannan Inhibits Rice Gruel-Induced Increases in Plasma Glucose and Insulin Levels.

Authors:  Akihiro Yoshida; Takao Kimura; Katsuhiko Tsunekawa; Osamu Araki; Kazumi Ushiki; Hirotaka Ishigaki; Yoshifumi Shoho; Itsumi Suda; Suguru Hiramoto; Masami Murakami
Journal:  Ann Nutr Metab       Date:  2020-07-13       Impact factor: 3.374

10.  Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.

Authors:  Nathan O Stitziel; Kathleen E Stirrups; Nicholas G D Masca; Jeanette Erdmann; Paola G Ferrario; Inke R König; Peter E Weeke; Thomas R Webb; Paul L Auer; Ursula M Schick; Yingchang Lu; He Zhang; Marie-Pierre Dube; Anuj Goel; Martin Farrall; Gina M Peloso; Hong-Hee Won; Ron Do; Erik van Iperen; Stavroula Kanoni; Jochen Kruppa; Anubha Mahajan; Robert A Scott; Christina Willenberg; Peter S Braund; Julian C van Capelleveen; Alex S F Doney; Louise A Donnelly; Rosanna Asselta; Piera A Merlini; Stefano Duga; Nicola Marziliano; Josh C Denny; Christian M Shaffer; Nour Eddine El-Mokhtari; Andre Franke; Omri Gottesman; Stefanie Heilmann; Christian Hengstenberg; Per Hoffman; Oddgeir L Holmen; Kristian Hveem; Jan-Håkan Jansson; Karl-Heinz Jöckel; Thorsten Kessler; Jennifer Kriebel; Karl L Laugwitz; Eirini Marouli; Nicola Martinelli; Mark I McCarthy; Natalie R Van Zuydam; Christa Meisinger; Tõnu Esko; Evelin Mihailov; Stefan A Escher; Maris Alver; Susanne Moebus; Andrew D Morris; Martina Müller-Nurasyid; Majid Nikpay; Oliviero Olivieri; Louis-Philippe Lemieux Perreault; Alaa AlQarawi; Neil R Robertson; Karen O Akinsanya; Dermot F Reilly; Thomas F Vogt; Wu Yin; Folkert W Asselbergs; Charles Kooperberg; Rebecca D Jackson; Eli Stahl; Konstantin Strauch; Tibor V Varga; Melanie Waldenberger; Lingyao Zeng; Aldi T Kraja; Chunyu Liu; George B Ehret; Christopher Newton-Cheh; Daniel I Chasman; Rajiv Chowdhury; Marco Ferrario; Ian Ford; J Wouter Jukema; Frank Kee; Kari Kuulasmaa; Børge G Nordestgaard; Markus Perola; Danish Saleheen; Naveed Sattar; Praveen Surendran; David Tregouet; Robin Young; Joanna M M Howson; Adam S Butterworth; John Danesh; Diego Ardissino; Erwin P Bottinger; Raimund Erbel; Paul W Franks; Domenico Girelli; Alistair S Hall; G Kees Hovingh; Adnan Kastrati; Wolfgang Lieb; Thomas Meitinger; William E Kraus; Svati H Shah; Ruth McPherson; Marju Orho-Melander; Olle Melander; Andres Metspalu; Colin N A Palmer; Annette Peters; Daniel Rader; Muredach P Reilly; Ruth J F Loos; Alex P Reiner; Dan M Roden; Jean-Claude Tardif; John R Thompson; Nicholas J Wareham; Hugh Watkins; Cristen J Willer; Sekkar Kathiresan; Panos Deloukas; Nilesh J Samani; Heribert Schunkert
Journal:  N Engl J Med       Date:  2016-03-02       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.